23ANDME PARTNERS WITH STANFORD RESEARCHER ON MPN
MPNRF | July 5, 2016
July 5, 2016
Researchers at Stanford have partnered with the genetic sequencing company 23andMe to study of 726 people with PV, ET and MF, compared to a control population from the 23andMe dataset. Dr. Jason Gotlib reports in Blood that individuals found in the control without an MPN, but with the JAK2 mutation have a predisposition to developing MPN as well as JAK2 V617F clonal hematopoiesis, a more common phenomenon that may foreshadow the development of an overt neoplasm.